文献速递MDS 与骨髓增殖性肿瘤白血病

Bexmarilimab联合阿扎胞苷治疗高危骨髓增生异常综合征及复发或难治性急性髓系白血病:多中心、单臂、1/2期试验剂量递增部分结果

Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial.
PubMed 文献 · Lancet Haematol · 2025-05-28

该多中心单臂1/2期试验剂量递增部分纳入33例高危骨髓增生异常综合征或复发/难治性急性髓系白血病患者,接受Bexmarilimab(1.0、3.0、6.0 mg/kg静脉每周一次)联合阿扎胞苷治疗。未达到最大耐受剂量,未出现剂量限制性毒性,2期推荐扩展剂量为6.0 mg/kg(用于低甲基化药物无应答的骨髓增生异常综合征患者)。总客观缓解率为45%(15/33,95%CI 28-62)。

要点

  • Bexmarilimab联合阿扎胞苷未出现剂量限制性毒性,未达到最大耐受剂量。
  • 2期推荐扩展剂量为6.0 mg/kg,用于低甲基化药物无应答的骨髓增生异常综合征患者。
  • 总客观缓解率为45%(15/33,95%CI 28-62)。

核心结论

  • Bexmarilimab联合阿扎胞苷的安全性可控,与阿扎胞苷一致,在高危骨髓增生异常综合征患者中显示出有前景的临床活性。

研究设计与样本

  • 多中心、单臂、1/2期研究,剂量递增部分在芬兰和美国的六个中心进行。
  • 纳入33例患者(14例骨髓增生异常综合征,19例复发或难治性急性髓系白血病),无慢性粒单核细胞白血病患者。
  • 患者接受Bexmarilimab(1.0、3.0、6.0 mg/kg静脉每周一次,28天周期)联合阿扎胞苷按标签给药。
  • 主要结局为安全性(剂量限制性毒性的发生率和频率、不良事件的频率和严重程度)以及确定最大耐受剂量和2期推荐扩展剂量,采用贝叶斯最优区间设计。

主要发现

  • 未达到最大耐受剂量,未出现剂量限制性毒性。
  • 2期推荐扩展剂量为6.0 mg/kg,用于低甲基化药物无应答的骨髓增生异常综合征患者。
  • 最常见的3-4级治疗中出现的不良事件为发热性中性粒细胞减少(8例[24%])、贫血(7例[21%])和血小板减少(5例[15%])。
  • 治疗相关严重不良事件4例:1.0 mg/kg组1例、3.0 mg/kg组2例、6.0 mg/kg组1例,包括皮疹(3级)、毛细血管渗漏综合征(3级)、隐源性机化性肺炎(3级)和噬血细胞性淋巴组织细胞增生症(5级,导致1例死亡)。
  • 总客观缓解率为45%(15/33;95%CI 28-62)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bexmarilimab blocks Clever-1 on macrophages to enhance antigen presentation and T cell activation. Because Clever-1 is expressed by myeloid leukaemia cells, bexmarilimab may combat leukaemia and influence the tumour microenvironment to augment the effectiveness of standard-of-care therapy in patients with myelodysplastic syndrome and acute myeloid leukaemia. The aim of this study was to determine the safety of bexmarilimab in combination with standard-of-care treatment in myelodysplastic syndrome and acute myeloid leukaemia and to identify the recommended dose for expansion of bexmarilimab in combination with standard of care. METHODS: The phase 1 dose-escalation part of this multicentre, single-arm, phase 1/2 study was done at six centres in Finland and the USA. Patients aged 18 years or older (Eastern Cooperative Oncology Group performance status of 2 or less) with myelodysplastic syndrome (2016 WHO) with a Revised International Prognostic Scoring System (IPPS-R) score of 3·5 or more for USA (3·0 for the European Union), chronic myelomonocytic leukaemia (2016 WHO) with 10-19% marrow blasts, myelodysplastic syndrome or chronic myelomonocytic leukaemia with no response to or disease progression during hypomethylating agent treatment, or relapsed or refractory acute myeloid leukaemia were treated with escalating doses of bexmarilimab (1·0 mg/kg, 3·0 mg/kg, and 6·0 mg/kg, intravenous, once weekly, 28-day cycle) in combination with azacitidine, administered as per label. Here we report the phase 1 part of the study, for which the primary outcome was safety (the incidence and frequency of dose limiting toxicities and the frequency and severity of adverse events) as well as the determination of the maximum tolerated dose and recommended expansion dose for the phase 2 part using a Bayesian optimal interval design. All patients receiving at least one dose of bexmarilimab were included in safety analyses, and those with a post-baseline activity assessment were included in activity analyses. This trial is registered with ClinicalTrials.gov (NCT05428969) and EudraCT (2021-002104-12) databases. Phase 2 of the study is ongoing in patients with myelodysplastic syndrome with no response to hypomethylating agent. FINDINGS: Between June 2, 2022, and Dec 7, 2023, 33 patients (14 with myelodysplastic syndrome, 19 with relapsed or refractory acute myeloid leukaemia) were enrolled in phase 1; no patients with chronic myelomonocytic leukaemia were identified. 19 (58%) patients were male and 14 (42%) were female, and 24 (73%) patients were non-Hispanic ethnicity, and eight (24%) were White. Median follow-up time for all patients was 6·2 months (IQR 3·5-10·7). The maximum tolerated dose was not reached, and the recommended expansion dose for phase 2 was established as 6·0 mg/kg in patients with myelodysplastic syndrome with no response to hypomethylating agents. There were no dose-limiting toxicities. The most common grade 3-4 treatment-emergent adverse events were febrile neutropenia (n=8 [24%]), anemia (n=7 [21%]), and thrombocytopenia (n=5 [15%]). Treatment-emergent deaths occurred as a result of sepsis (n=1 [3%]), neutropenic infection (n=1 [3%]), and haemophagocytic lymphohistiocytosis (n=1 [3%]). Four patients presented treatment-related serious adverse events, one patient in the 1·0 mg/kg group, two in the 3·0 mg/kg group and one in the 6·0 mg/kg group. These included rash (grade 3), capillary leak syndrome (grade 3), cryptogenic organising pneumonia (grade 3) and haemophagocytic lymphohistiocytosis (grade 5) which led to one death. The objective response rate was 45% (15 of 33; 95% CI 28-62) across all doses. INTERPRETATION: Bexmarilimab in combination with azacitidine has a manageable safety profile, consistent with azacitidine, and shows promising clinical activity in patients with high-risk myelodysplastic syndrome. FUNDING: Faron Pharmaceuticals.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Kontro M, Stein AS, Pyörälä M, et al. Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial. Lancet Haematol. 2025. PMID: 40449509. doi:10.1016/S2352-3026(25)00103-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。